Traders should monitor whether Mayo Clinic exercises its option to purchase the additional shares, which would provide SANA with another $25 million in funding. The partnership with Mayo Clinic for diabetes therapies could lead to future value creation, but investors should track the progress of these development programs.
Price Chart
Executive Summary
Sana Biotechnology entered into a stock purchase agreement with Mayo Clinic, selling 7.5 million shares for $25 million upfront, with an option for Mayo Clinic to purchase an additional 7.5 million shares for another $25 million. The proceeds will be used for developing diabetes therapies, and Mayo Clinic agreed to a six-month lock-up period.
Key Facts
- Sana Biotechnology sold 7,507,507 shares to Mayo Clinic for $24.999 million at $3.33 per share
- Mayo Clinic has the option to purchase an additional 7,507,507 shares for $24.999 million
- Proceeds will be used for developing products including SC451 and genetically modified stem-cell derived islet cell products
- Mayo Clinic agreed to a lock-up period of six months from the initial closing
- Sana's cash position of $138.4 million as of December 31, 2025, plus the anticipated $24.9 million from this transaction, is expected to fund operations into 2027
Financial Impact
Immediate $24.999 million in gross proceeds from the initial share sale, with potential for an additional $24.999 million if Mayo Clinic exercises its option
Risk Factors
- Dilution from the potential additional share issuance
- Dependence on successful development of diabetes therapies
- Mayo Clinic may choose not to exercise its option for additional shares
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152868 |
| Document: sana-20260410.htm | 0001193125-26-152868 |
| Document: sana-ex5_1.htm | 0001193125-26-152868 |
| Document: 0001193125-26-152868-index-headers.html | 0001193125-26-152868 |
| Document: 0001193125-26-152868-index.html | 0001193125-26-152868 |
| Document: 0001193125-26-152868.txt | 0001193125-26-152868 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $3.79 $3.17 | ▼ −16.36% | ▼ −15.30% | $2.87 (−24.41%) |
Aug 10, 2026 7w ago | Press Release | $3.79 $3.17 | ▼ −16.36% | ▼ −15.30% | $2.87 (−24.41%) |
May 11, 2026 20w ago | 8-K | $3.26 $2.82 | ▼ −13.50% | ▼ −11.77% | $2.87 (−12.12%) |
May 11, 2026 20w ago | Press Release | $3.26 $2.82 | ▲ +13.50% | ▲ +11.77% | $2.87 (+12.12%) |
Apr 24, 2026 23w ago | DEFA14A | $3.29 $3.15 | ▼ −4.26% | ▼ −8.28% | $2.87 (−12.92%) |
Apr 24, 2026 23w ago | 8-K | $3.29 $3.15 | ▼ −4.26% | ▼ −8.28% | $2.87 (−12.92%) |
Apr 13, 2026 24w ago | 8-K | $3.48 $3.56 | ▲ +2.30% | ▼ −4.00% | $2.87 (−17.67%) |
Apr 13, 2026 24w ago | Press Release | $3.48 $3.56 | ▲ +2.30% | ▼ −4.00% | $2.87 (−17.67%) |
Mar 13, 2026 29w ago | Press Release | $3.36 $3.21 | ▼ −4.46% | ▼ −8.05% | $2.87 (−14.73%) |
Mar 3, 2026 30w ago | Press Release | $3.82 $3.05 | ▼ −20.16% | ▼ −15.74% | $2.87 (−25.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access